Vianautis
Deborah Wright is a Project Manager currently employed at Vianautis since September 2024, having previously held Project Manager, Project Coordinator, and Scientist II roles at MiNK Therapeutics from October 2018 to April 2024. At MiNK Therapeutics, responsibilities included managing a CAR iNKT project and developing a pipeline for isolating T cell clones. Prior to this, Deborah served as a Research Scientist at Immunocore from January 2010 to September 2018, focusing on isolating T cells with TCRs specific to cancer peptides. Deborah began their career as a Senior Finisher at the Wellcome Trust Sanger Institute from November 2003 to December 2006, working in computational biology and genome sequencing. Educational qualifications include a PhD in Virology from the University of Cambridge and a BS in Medical Biochemistry from the University of Sheffield.
This person is not in any teams
Vianautis
ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and serial entrepreneur, Dr Francesca Crawford. The company’s core mission is to exploit the unique capabilities of the revolutionary polyNaut® technology. PolyNaut® is a versatile nano-engineered polymer technology designed for targeted intracellular delivery. This innovative technology enables polymer nanoparticles to deliver a wide range of payloads from small molecules to genetic materials creating ‘a bionic nanoparticle.’ The highly adaptable polymer structure of polyNaut® can be formulated to encapsulate a wide array of genetic cargoes, with sizes exceeding current standards for viral and non-viral delivery. Notably, it enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling. PolyNaut® is set apart from conventional non-viral delivery technologies through its remarkable ability to target specific cells and penetrate biological barriers, including the challenging blood-brain barrier. PolyNaut® nanoparticles, when functionalised for CNS delivery through transcytosis, exhibit exceptional brain uptake. Deploying its state-of-the-art polyNaut® platform, ViaNautis is at the forefront of pioneering new therapies for CNS diseases and cystic fibrosis. The company is actively building an internal pipeline and collaborating with leading pharmaceutical and biotech companies to unlock the potential of promising genetic molecules as well as new therapeutic platforms.